Buruli ulcer

References

• Walsh DS, Portaels F, Meyers WM. Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection. Dermatol Clin 2011; 29:1 - 8; http://dx.doi.org/10.1016/j.det.2010.09.006; PMID: 21095521
   PubMed Web of Science ®Google Scholar
• Fyfe JA, Lavender CJ, Handasyde KA, Legione AR, O'Brien CR, Stinear TP, et al. A major role for mammals in the ecology of Mycobacterium ulcerans.. PLoS Negl Trop Dis 2010; 4:e791; http://dx.doi.org/10.1371/journal.pntd.0000791; PMID: 20706592
   PubMed Web of Science ®Google Scholar
• Stinear T, Davies JK, Jenkin GA, Hayman JA, Oppedisano F, Johnson PD. Identification of Mycobacterium ulcerans in the environment from regions in Southeast Australia in which it is endemic with sequence capture-PCR. Appl Environ Microbiol 2000; 66:3206 - 13; http://dx.doi.org/10.1128/AEM.66.8.3206-3213.2000; PMID: 10919771
   PubMed Web of Science ®Google Scholar
• Merritt RW, Walker ED, Small PL, Wallace JR, Johnson PD, Benbow ME, et al. Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis 2010; 4:e911; http://dx.doi.org/10.1371/journal.pntd.0000911; PMID: 21179505
   PubMed Web of Science ®Google Scholar
• Johnson PD, Azuolas J, Lavender CJ, Wishart E, Stinear TP, Hayman JA, et al. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis 2007; 13:1653 - 60; PMID: 18217547
   PubMed Web of Science ®Google Scholar
• Vandelannoote K, Durnez L, Amissah D, Gryseels S, Dodoo A, Yeboah S, et al. Application of real-time PCR in Ghana, a Buruli ulcer-endemic country, confirms the presence of Mycobacterium ulcerans in the environment. FEMS Microbiol Lett 2010; 304:191 - 4; http://dx.doi.org/10.1111/j.1574-6968.2010.01902.x; PMID: 20146745
   PubMed Web of Science ®Google Scholar
• Bamberger D, Jantzer N, Leidner K, Arend J, Efferth T.. Fighting mycobacterial infections by antibiotics, phytochemicals and vaccines. Microbes Infect 2011; 13:613 - 23; http://dx.doi.org/10.1016/j.micinf.2010.09.002; PMID: 20832501
   PubMed Web of Science ®Google Scholar
• Silva MT, Portaels F, Pedrosa J. Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis 2009; 9:699 - 710; http://dx.doi.org/10.1016/S1473-3099(09)70234-8; PMID: 19850228
   PubMed Web of Science ®Google Scholar
• O'Brien DP, Hughes AJ, Cheng C, Henry MJ, Callan P, McDonald A, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007; 186:58 - 61; PMID: 17223763
   PubMed Web of Science ®Google Scholar
• Touw J, Langendijk EM, Stoner GL, Belehu A. Humoral immunity in leprosy: immunoglobulin G and M antibody responses to Mycobacterium leprae in relation to various disease patterns. Infect Immun 1982; 36:885 - 92; PMID: 7047400
   PubMed Web of Science ®Google Scholar
• Demkow U, Bialas-Chromiec B, Filewska M, Sobiecka M, Kus J, Szturmowicz M, et al. Humoral immune response against mycobacterial antigens in bronchoalveolar fluid from tuberculosis patients. J Physiol Pharmacol 2005; 56:Suppl 4 79 - 84; PMID: 16204779
   PubMedGoogle Scholar
• Gooding TM, Johnson PD, Smith M, Kemp AS, Robins-Browne RM. Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun 2002; 70:5562 - 7; http://dx.doi.org/10.1128/IAI.70.10.5562-5567.2002; PMID: 12228283
   PubMed Web of Science ®Google Scholar
• Prévot G, Bourreau E, Pascalis H, Pradinaud R, Tanghe A, Huygen K, et al. Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun 2004; 72:958 - 65; http://dx.doi.org/10.1128/IAI.72.2.958-965.2004; PMID: 14742541
   PubMed Web of Science ®Google Scholar
• Westenbrink BD, Stienstra Y, Huitema MG, Thompson WA, Klutse EO, Ampadu EO, et al. Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol 2005; 12:125 - 9; PMID: 15642996
   PubMedGoogle Scholar
• Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep 2008; 25:447 - 54; http://dx.doi.org/10.1039/b803101k; PMID: 18497894
   PubMed Web of Science ®Google Scholar
• Converse PJ, Almeida DV, Nuermberger EL, Grosset JH. BCG-mediated protection against Mycobacterium ulcerans infection in the mouse. PLoS Negl Trop Dis 2011; 5:e985; http://dx.doi.org/10.1371/journal.pntd.0000985; PMID: 21423646
   PubMed Web of Science ®Google Scholar
• Boulkroun S, Guenin-Mace L, Thoulouze MI, Monot M, Merckx A, Langsley G, et al. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol 2010; 184:1436 - 44; http://dx.doi.org/10.4049/jimmunol.0902854; PMID: 20042571
   PubMed Web of Science ®Google Scholar
• Kishi Y. Chemistry of mycolactones, the causative toxins of Buruli ulcer. Proc Natl Acad Sci USA 2011; 108:6703 - 8; http://dx.doi.org/10.1073/pnas.1015252108; PMID: 21383136
   PubMed Web of Science ®Google Scholar
• Simmonds RE, Lali FV, Smallie T, Small PL, Foxwell BM. Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol 2009; 182:2194 - 202; http://dx.doi.org/10.4049/jimmunol.0802294; PMID: 19201873
   PubMed Web of Science ®Google Scholar
• George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999; 283:854 - 7; http://dx.doi.org/10.1126/science.283.5403.854; PMID: 9933171
   PubMed Web of Science ®Google Scholar
• Phillips R, Sarfo FS, Guenin-Mace L, Decalf J, Wansbrough-Jones M, Albert ML, et al. Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. J Infect Dis 2009; 200:1675 - 84; http://dx.doi.org/10.1086/646615; PMID: 19863437
   PubMed Web of Science ®Google Scholar
• Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, Tanguy M, et al. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 2005; 7:1187 - 96; http://dx.doi.org/10.1111/j.1462-5822.2005.00546.x; PMID: 16008585
   PubMed Web of Science ®Google Scholar
• Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, Pedrosa J. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 2007; 75:3979 - 88; http://dx.doi.org/10.1128/IAI.00290-07; PMID: 17517872
   PubMed Web of Science ®Google Scholar
• Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, Portaels F, et al. Evidence for an intramacrophage growth phase of Mycobacterium ulcerans.. Infect Immun 2007; 75:977 - 87; http://dx.doi.org/10.1128/IAI.00889-06; PMID: 17145944
   PubMed Web of Science ®Google Scholar
• Huygen K, Adjei O, Affolabi D, Bretzel G, Demangel C, Fleischer B, et al. Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol (Berl) 2009; 198:69 - 77; http://dx.doi.org/10.1007/s00430-009-0109-6; PMID: 19198877
   PubMed Web of Science ®Google Scholar
• Tanghe A, Content J, Van Vooren JP, Portaels F, Huygen K. Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun 2001; 69:5403 - 11; http://dx.doi.org/10.1128/IAI.69.9.5403-5411.2001; PMID: 11500410
   PubMed Web of Science ®Google Scholar
• Diaz D, Dobeli H, Yeboah-Manu D, Mensah-Quainoo E, Friedlein A, Soder N, et al. Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans.. Clin Vaccine Immunol 2006; 13:1314 - 21; http://dx.doi.org/10.1128/CVI.00254-06; PMID: 17021247
   PubMed Web of Science ®Google Scholar
• Pidot SJ, Porter JL, Marsollier L, Chauty A, Migot-Nabias F, Badaut C, et al. Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics. PLoS Negl Trop Dis 2010; 4:e872; http://dx.doi.org/10.1371/journal.pntd.0000872; PMID: 21072233
   PubMedGoogle Scholar
• Huygen K. Prospects for vaccine development against Buruli disease. Expert Rev Vaccines 2003; 2:561 - 9; http://dx.doi.org/10.1586/14760584.2.4.561; PMID: 14711340
   PubMedGoogle Scholar
• Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, Brosch R, et al. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans.. Proc Natl Acad Sci USA 2004; 101:1345 - 9; http://dx.doi.org/10.1073/pnas.0305877101; PMID: 14736915
   PubMed Web of Science ®Google Scholar
• Mosi L, Williamson H, Wallace JR, Merritt RW, Small PL. Persistent association of Mycobacterium ulcerans with West African predaceous insects of the family belostomatidae. Appl Environ Microbiol 2008; 74:7036 - 42; http://dx.doi.org/10.1128/AEM.01234-08; PMID: 18836026
   PubMed Web of Science ®Google Scholar
• Thaiss CA, Kaufmann SH. Toward novel vaccines against tuberculosis: current hopes and obstacles. Yale J Biol Med 2010; 83:209 - 15; PMID: 21165340
   PubMedGoogle Scholar
• Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun 2005; 73:4676 - 83; http://dx.doi.org/10.1128/IAI.73.8.4676-4683.2005; PMID: 16040980
   PubMed Web of Science ®Google Scholar
• Magalhaes I, Sizemore DR, Ahmed RK, Mueller S, Wehlin L, Scanga C, et al. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS ONE 2008; 3:e3790; http://dx.doi.org/10.1371/journal.pone.0003790; PMID: 19023426
   PubMed Web of Science ®Google Scholar
• Von Eschen K, Morrison R, Braun M, Ofori-Anyinam O, De KE, Pavithran P, et al. The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum Vaccin 2009; 5:475 - 82; PMID: 19587528
   PubMed Web of Science ®Google Scholar
• Skeiky YA, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, Goetz MA, et al. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine 2010; 28:1084 - 93; http://dx.doi.org/10.1016/j.vaccine.2009.10.114; PMID: 19896449
   PubMed Web of Science ®Google Scholar
• van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, Bang P, et al. Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 2011; 29:2100 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.12.135; PMID: 21256189
   PubMed Web of Science ®Google Scholar
• McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240 - 4; http://dx.doi.org/10.1038/nm1128; PMID: 15502839
   PubMed Web of Science ®Google Scholar
• Martín C. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?. Eur Respir J 2005; 26:162 - 7; http://dx.doi.org/10.1183/09031936.05.00109904; PMID: 15994403
   PubMed Web of Science ®Google Scholar
• BCG vaccination against Mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda. Lancet 1969; 1:111 - 5; PMID: 4178240
   PubMed Web of Science ®Google Scholar
• Smith PG, Revill WD, Lukwago E, Rykushin YP. The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans R Soc Trop Med Hyg 1976; 70:449 - 57; http://dx.doi.org/10.1016/0035-9203(76)90128-0; PMID: 841647
   PubMed Web of Science ®Google Scholar
• Amofah GK, Sagoe-Moses C, Adjei-Acquah C, Frimpong EH. Epidemiology of Buruli ulcer in Amansie West district, Ghana. Trans R Soc Trop Med Hyg 1993; 87:644 - 5; http://dx.doi.org/10.1016/0035-9203(93)90272-R; PMID: 8296362
   PubMed Web of Science ®Google Scholar
• Portaels F, Aguiar J, Debacker M, Guedenon A, Steunou C, Zinsou C, et al. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 2004; 72:62 - 5; http://dx.doi.org/10.1128/IAI.72.1.62-65.2004; PMID: 14688081
   PubMed Web of Science ®Google Scholar
• Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003; 9:533 - 9; http://dx.doi.org/10.1038/nm859; PMID: 12692540
   PubMed Web of Science ®Google Scholar
• Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996; 348:17 - 24; http://dx.doi.org/10.1016/S0140-6736(96)02166-6; PMID: 8691924
   PubMed Web of Science ®Google Scholar
• Barreto ML, Pereira SM, Pilger D, Cruz AA, Cunha SS, Sant'anna C, et al. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: Second report of the BCG-REVAC cluster-randomised trial. Vaccine 2011; 29:4875 - 7; http://dx.doi.org/10.1016/j.vaccine.2011.05.023; PMID: 21616115
   PubMed Web of Science ®Google Scholar
• Basaraba RJ, Izzo AA, Brandt L, Orme IM. Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine 2006; 24:280 - 6; http://dx.doi.org/10.1016/j.vaccine.2005.07.103; PMID: 16153758
   PubMed Web of Science ®Google Scholar
• Tanghe A, Adnet PY, Gartner T, Huygen K. A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice. Infect Immun 2007; 75:2642 - 4; http://dx.doi.org/10.1128/IAI.01622-06; PMID: 17325046
   PubMed Web of Science ®Google Scholar
• Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, Small PL. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 2005; 7:1295 - 304; http://dx.doi.org/10.1111/j.1462-5822.2005.00557.x; PMID: 16098217
   PubMed Web of Science ®Google Scholar
• Kamath AT, Fruth U, Brennan MJ, Dobbelaer R, Hubrechts P, Ho MM, et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 2005; 23:3753 - 61; http://dx.doi.org/10.1016/j.vaccine.2005.03.001; PMID: 15893612
   PubMed Web of Science ®Google Scholar
• Tanghe A, Dangy JP, Pluschke G, Huygen K. Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting. PLoS Negl Trop Dis 2008; 2:e199; http://dx.doi.org/10.1371/journal.pntd.0000199; PMID: 18350112
   PubMed Web of Science ®Google Scholar
• Coutanceau E, Legras P, Marsollier L, Reysset G, Cole ST, Demangel C. Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer. Microbes Infect 2006; 8:2075 - 81; http://dx.doi.org/10.1016/j.micinf.2006.03.009; PMID: 16781179
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Bezouska K, Vavrincova P, Sedlacek P, Hromadnikova I. Humoral response against Mycobacterium bovis Hsp65 derived fragments in children and young people with various disorders. J Immunoassay Immunochem 2008; 29:281 - 98; http://dx.doi.org/10.1080/15321810802119265; PMID: 18569376
   PubMed Web of Science ®Google Scholar
• Huber CA, Ruf MT, Pluschke G, Kaser M. Independent loss of immunogenic proteins in Mycobacterium ulcerans suggests immune evasion. Clin Vaccine Immunol 2008; 15:598 - 606; http://dx.doi.org/10.1128/CVI.00472-07; PMID: 18256209
   PubMed Web of Science ®Google Scholar
• Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KL, et al. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun 2007; 75:941 - 9; http://dx.doi.org/10.1128/IAI.01137-06; PMID: 17145953
   PubMed Web of Science ®Google Scholar
• Lin MY, Reddy TB, Arend SM, Friggen AH, Franken KL, van Meijgaarden KE, et al. Cross-reactive immunity to Mycobacterium tuberculosis DosR regulon-encoded antigens in individuals infected with environmental, nontuberculous mycobacteria. Infect Immun 2009; 77:5071 - 9; http://dx.doi.org/10.1128/IAI.00457-09; PMID: 19737909
   PubMed Web of Science ®Google Scholar
• Marsollier L, Deniaux E, Brodin P, Marot A, Wondje CM, Saint-Andre JP, et al. Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. PLoS Med 2007; 4:e64; http://dx.doi.org/10.1371/journal.pmed.0040064; PMID: 17326707
   PubMed Web of Science ®Google Scholar
• Benbow ME, Williamson H, Kimbirauskas R, McIntosh MD, Kolar R, Quaye C, et al. Aquatic invertebrates as unlikely vectors of Buruli ulcer disease. Emerg Infect Dis 2008; 14:1247 - 54; http://dx.doi.org/10.3201/eid1408.071503; PMID: 18680648
   PubMed Web of Science ®Google Scholar
• Shen NL, Hartikka J, Horn NA, Manthorpe M, Marquet M. Development and characterization of lyophilized DNA vaccine formulations. Methods Mol Med 2000; 29:23 - 34; PMID: 21374306
   PubMedGoogle Scholar
• Fraga AG, Cruz A, Martins TG, Torrado E, Saraiva M, Pereira DR, et al. Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun 2011; 79:421 - 30; http://dx.doi.org/10.1128/IAI.00820-10; PMID: 20974825
   PubMed Web of Science ®Google Scholar
• Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, Adeye A, et al. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis 2011; 52:94 - 6; http://dx.doi.org/10.1093/cid/ciq072; PMID: 21148526
   PubMed Web of Science ®Google Scholar
• Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, Grosset JH. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice. PLoS Negl Trop Dis 2011; 5:e933; http://dx.doi.org/10.1371/journal.pntd.0000933; PMID: 21245920
   PubMed Web of Science ®Google Scholar
• Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, Asamoa K, et al. Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis 2003; 9:651 - 6; PMID: 12780997
   PubMed Web of Science ®Google Scholar